東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Development of novel antidote contro...

Duke University., Genetics and Genomics.

FindBook

Google Book

Amazon

博客來

Development of novel antidote controlled antithrombotic aptamers.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Development of novel antidote controlled antithrombotic aptamers./
作者:	Oney, Sabah.
面頁冊數:	197 p.
附註:	Adviser: Bruce A. Sullenger.
Contained By:	Dissertation Abstracts International69-02B.
標題:	Biology, Genetics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3297725
ISBN:	9780549486169

Development of novel antidote controlled antithrombotic aptamers.
Oney, Sabah.

Development of novel antidote controlled antithrombotic aptamers. - 197 p.

Adviser: Bruce A. Sullenger.

Thesis (Ph.D.)--Duke University, 2008.

Thrombosis is initiated by platelets and leads to cardio-, cerebro-, and peripheral vascular disease, the leading causes of morbidity and mortality in the western world. Antiplatelet drugs have improved clinical outcomes for thrombosis patients. However, their expanded use is limited by hemorrhage at high concentrations and sub-therapeutic activity at lower doses. Thus, development of new antiplatelet agents with improved safety and efficacy is a medical priority.

ISBN: 9780549486169Subjects--Topical Terms:

1017730
Biology, Genetics.

Development of novel antidote controlled antithrombotic aptamers.
LDR:03566nam 2200361 a 45 001 852085
005 20100629
008 100629s2008 ||||||||||||||||| ||eng d
020 $a 9780549486169
035 $a (UMI)AAI3297725
035 $a AAI3297725
040 $a UMI $c UMI
100 1 $a Oney, Sabah. $3 1017783
245 1 0 $a Development of novel antidote controlled antithrombotic aptamers.
300 $a 197 p.
500 $a Adviser: Bruce A. Sullenger.
500 $a Source: Dissertation Abstracts International, Volume: 69-02, Section: B, page: 0812.
502 $a Thesis (Ph.D.)--Duke University, 2008.
520 $a Thrombosis is initiated by platelets and leads to cardio-, cerebro-, and peripheral vascular disease, the leading causes of morbidity and mortality in the western world. Antiplatelet drugs have improved clinical outcomes for thrombosis patients. However, their expanded use is limited by hemorrhage at high concentrations and sub-therapeutic activity at lower doses. Thus, development of new antiplatelet agents with improved safety and efficacy is a medical priority.
520 $a VWF is a multimeric plasma glycoprotein that plays a critical role in platelet-mediated thrombus formation and presents an attractive target for antiplatelet therapy. To this end, I have isolated and characterized aptamer molecules that bind to VWF with high affinity and have shown that some of these aptamer molecules could inhibit platelet activation/aggregation in vitro and in vivo. Furthermore, I designed antidote molecules that can reverse the effects of the aptamer molecules, restoring platelet function quickly and effectively. This project has yielded the first antidote controlled antiplatelet agent and may lead to significant improvements in thrombosis therapy.
520 $a Thrombin is a plasma protein that plays a critical role in thrombosis. Currently, available antithrombin agents are efficacious in preventing coagulation but do not significantly affect platelet activation and aggregation, both essential components of thrombus formation. Therefore, I tested two aptamer molecules that bind to mutually exclusive exosites on thrombin and, when used together, synergistically inhibit both coagulation and platelet activation. I demonstrated that this method could potentially lead to the development of effective antithrombotic therapies.
520 $a With an ever-increasing number of people taking multiple medications, the need to safely administer drugs and limit unintended side effects has never been greater. Antidote control remains the most direct means to counteract acute side effects of drugs but unfortunately it has been challenging and cost prohibitive to generate antidotes for most therapeutic agents. Therefore, I described the development of a set of antidote molecules that are capable of counteracting the effects of an entire class of therapeutic agents, i.e. aptamers, including those that I generated against VWF. I demonstrated that protein and polymer-based molecules that capture oligonucleotides can reverse the activity of aptamers in vitro and in vivo.
590 $a School code: 0066.
650 4 $a Biology, Genetics. $3 1017730
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0369
690 $a 0419
710 2 $a Duke University. $b Genetics and Genomics. $3 1017782
773 0 $t Dissertation Abstracts International $g 69-02B.
790 $a 0066
790 1 0 $a Chi, Jen-Tsan A. $e committee member
790 1 0 $a Hoffman, Maureane $e committee member
790 1 0 $a Marchuk, Douglas $e committee member
790 1 0 $a Ortel, Thomas $e committee member
790 1 0 $a Sullenger, Bruce A., $e advisor
791 $a Ph.D.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3297725